Review Series - January 1, 2015

The term 'aggressive B-cell lymphomas' has been applied to highly proliferative lymphomas that evolve clinically over weeks to months, and have been the focus of important advantages in clinical treatment strategies. The series highlights the evolution of our understanding of the biology of these lymphomas such that they are now defined as a heterogeneous group of diseases that requires tailored therapy. The aim of the series is to elucidate how this improved understanding of pathogenesis is leading to more effective treatment strategies and improved survival.